# Elizabeth M. Swisher

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/elizabeth-m-swisher/

## Facts

| Field | Value |
| --- | --- |
| Citations | 62,099 |
| Field | PARP inhibition in cancer therapy |
| h-index | 102 |
| i10-index | 238 |
| Last Known Institution | University of Washington |
| OpenAlex ID | https://openalex.org/A5084420374 |
| ORCID iD | 0000-0003-2331-0434 |
| Works | 748 |

## Researcher papers

- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Inherited Mutations in Women With Ovarian Carcinoma](https://scholariq.org/papers/inherited-mutations-in-women-with-ovarian-carcinoma/)
- [NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017](https://scholariq.org/papers/nccn-guidelines-insights-genetic-familial-high-risk-assessment-breast-and/)
- [Genetic/Familial High-Risk Assessment: Breast and Ovarian](https://scholariq.org/papers/genetic-familial-high-risk-assessment-breast-and-ovarian/)
- [Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/final-overall-survival-of-a-randomized-trial-of-bevacizumab-for-primary/)
- [<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma](https://scholariq.org/papers/i-brca-i-reversion-mutations-in-circulating-tumor-dna-predict-primary-and/)
- [Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2](https://scholariq.org/papers/antitumor-activity-and-safety-of-the-parp-inhibitor-rucaparib-in-patients-with/)
- [Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial](https://scholariq.org/papers/olaparib-and-specific-pi3k-inhibitor-alpelisib-for-patients-with-epithelial/)
- [Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)](https://scholariq.org/papers/molecular-and-clinical-determinants-of-response-and-resistance-to-rucaparib-for/)
- [APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma](https://scholariq.org/papers/apobec3b-upregulation-and-genomic-mutation-patterns-in-serous-ovarian-carcinoma/)

## Researcher topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)

## Researcher university

- [University of Washington](https://scholariq.org/institutions/university-of-washington/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.